Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Idiopathic Optic Nerve Glioma: A Case Report.
Cureus
December 2024
Department of Ophthalmology, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Pune, IND.
Optic nerve gliomas are tumors that develop along the optic nerve pathway, most often classified as pilocytic astrocytomas. These growths are typically benign, especially in young children between the ages of one and six years, while the rarer malignant types are generally more aggressive and tend to appear in adults. Characteristically slow-growing, optic nerve gliomas are commonly located in the pre-chiasmal part of the optic nerve but can extend to post-chiasmal regions and into the brain if left untreated.
View Article and Find Full Text PDFOptic nerve glioma successfully treated with definitive intensity-modulated radiotherapy in a limited-resource setting: a case report.
Ecancermedicalscience
November 2024
National Centre for Radiotherapy, Oncology and Nuclear Medicine, Korle Bu Teaching Hospital, Accra, Ghana.
Optic nerve gliomas (ONG) are benign central nervous system tumours and the most common tumours of the optic nerve in children, often occurring before age 20. These tumours are slow-growing and can be treated with surgery and/or radiation therapy. Surgical resection is, however, associated with significant morbidity and loss of vision in the affected eye.
View Article and Find Full Text PDFFree-hand Frameless Pinless Electromagnetic-Navigation (AXIEM™)-Guided Brain Lesion Biopsies: An Institution Based Experience from a Low-Middle-Income Country.
Pak J Med Sci
December 2024
Dr. Asif Bashir, MD, FAANS, FACS Professor of Neurosurgery, Department of Neurosurgery Unit-I, Punjab Institute of Neurosciences, Lahore, Pakistan.
Objectives: To evaluate the precision and safety of a novel technique of free-hand frameless pinless AXIEM™-based navigation guided biopsy of deep-seated brain lesions in a low-middle income country.
Methods: This retrospective study included 45 patients who underwent free-hand frameless pinless AXIEM™-based navigation guided biopsy of deep-seated brain lesions using the Medtronic-Stealth S7 system over a 5-year period (January 2019 to December 2023) at the Department of Neurosurgery, Punjab Institute of Neurosciences, Lahore, Pakistan.
Results: A total of 45 patients were included in this study.
The anti-glypican 1 AT101 antibody as targeting agent to effectively deliver chitosan nanobubbles to glioblastoma cells.
Nanomedicine (Lond)
January 2025
Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico di Aviano, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Aviano, Italy.
Background: Recently, we developed AT101, an IgM-class mouse monoclonal antibody directed against glypican-1 (GPC1), a proteoglycan that can be considered as useful target for glioblastoma multiforme (GBM) treatment being specifically and highly expressed on GBM cell surface. Here, we proposed the use of AT101 as targeting agent in a drug delivery nanoplatfom to effectively deliver chitosan nanobubbles (NBs) for GBM treatment.
Methods: Chitosan NBs were prepared and conjugated with AT101 or left unconjugated as control.
A case report of surgery-radiotherapy-chemotherapy cured primary diffuse large B-cell lymphoma of the central nervous system associated with HIV infection.
Diagn Pathol
November 2024
Department of Infectious Diseases, The Fourth People's Hospital of Nanning, Nanning, China.
Background: Diffuse large B-cell lymphoma (DLBCL) is one of the most common complications in patients with Acquired Immune Deficiency Syndrome (AIDS), yet its prognosis is generally poor. The impact of surgery on DLBCL remains controversial. We present a case of DLBCL associated with HIV infection, in which the patient achieved complete remission following surgical removal, radiotherapy, and sequential dose-adjusted EPOCH (DA-EPOCH) chemotherapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!